ImmunityBio, Inc. (IBRX) 8-K Current Report — February 23, 2026
Filed: February 23, 2026
Health Care
Biological Products, (No Diagnostic Substances)ImmunityBio, Inc. (IBRX) 8-K current report filed with SEC EDGAR on February 23, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items1 item
- Item 2.02: Results of Operations and Financial Condition
ImmunityBio, Inc. 8-K Feb 23, 2026 Event Analysis
Item 2.02 · Results of Operations and Financial Condition
- • Q4 and full-year 2025 financial results released Feb 23, 2026; details in Exhibit 99.1
- • Filing covers period ending Dec 31, 2025, including balance sheet position as of that date
Get deeper insights on ImmunityBio, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.